Reversal of functional defects in highly differentiated young and old CD8 T cells by PDL blockade

Immunology - Tập 135 Số 4 - Trang 355-363 - 2012
Siân M. Henson1, R. Macaulay1, Ornella Franzese2, Arne N. Akbar1
1Division of Infection & Immunity, University College London, London, UK
2Department of Neuroscience, University of Tor Vergata, Rome, Italy

Tóm tắt

Summary

Highly differentiated CD8+ CD28 CD27 T cells have short telomeres, defective telomerase activity and reduced capacity for proliferation. In addition, these cells express increased levels of inhibitory receptors and display defective Akt(ser473) phosphorylation following activation. It is not known whether signalling via programmed death 1 (PD‐1) contributes to any of the attenuated differentiation‐related functional changes in CD8+ T cells. To address this we blocked PD‐1 signalling during T‐cell receptor (TCR) activation using antibodies against PD‐1 ligand 1 (PDL1) and PDL2. This resulted in a significant enhancement of Akt(ser473) phosphorylation and TCR‐induced proliferative activity of highly differentiated CD8+ CD28 CD27 T cells. In contrast, the reduced telomerase activity in these cells was not altered by blockade of PDL1/2. We also demonstrate that PD‐1 signalling can inhibit the proliferative response in primary human CD8+ T cells from both young and older humans. These data collectively highlight that some, but not all, functional changes that arise during progressive T‐cell differentiation and during ageing are maintained actively by inhibitory receptor signalling.

Từ khóa


Tài liệu tham khảo

10.1038/nri1440

10.1016/j.immuni.2006.05.001

10.1016/S0264-410X(99)00489-2

10.1038/25374

10.1038/ni1033

10.1084/jem.20040437

10.1016/j.coi.2005.07.019

10.1016/j.exger.2006.09.005

10.4049/jimmunol.178.12.7710

10.1016/j.cellsig.2005.08.016

10.1016/j.mad.2007.10.005

10.1016/0531-5565(94)90073-6

10.1016/j.exger.2006.11.016

10.1016/j.clim.2007.12.002

10.1111/j.0105-2896.2005.00259.x

10.1182/blood-2007-07-104604

10.1182/blood-2009-01-199588

10.4049/jimmunol.175.12.8218

10.1182/blood-2002-02-0657

10.1038/nature05115

10.1084/jem.20061496

10.1038/nm1482

10.1038/ni.1679

10.1038/ni1515

10.1084/jem.20081398

10.1084/jem.20100637

10.1084/jem.20100643

10.1016/j.immuni.2007.09.006

10.1146/annurev.immunol.23.021704.115611

10.1128/MCB.25.21.9543-9553.2005

10.1016/j.semcdb.2003.12.024

10.4049/jimmunol.169.4.1984

10.1016/j.imlet.2004.10.003

10.1038/nri1254

10.1002/cyto.a.20643

10.1002/j.1460-2075.1996.tb01045.x

10.1016/j.cell.2006.08.033

10.1111/j.1582-4934.2005.tb00337.x

10.1371/journal.ppat.1000313

10.1073/pnas.1003345107

10.1182/blood-2008-01-135442

10.1073/pnas.0811139106

10.1038/nri2959

10.4049/jimmunol.1100978

10.1038/nature04444

10.1038/ni1443

10.1182/blood-2004-04-1596

10.1093/intimm/dxm004

10.1111/j.1600-065X.2009.00767.x

10.1016/j.immuni.2007.05.016

10.4049/jimmunol.0803449

10.1089/vim.1994.7.31

10.1016/S1386-6532(01)00246-3